Nautilus Biotechnology, Inc. (NAUT) Stock

Nautilus Biotechnology, Inc. (NAUT) is a Technology stock trading at $2.26 (as of 2026-06-18), with a market capitalization of $348.20M and a trailing P/E of -5.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Nautilus Biotechnology, Inc. is a development-stage life sciences company developing platform technology for measuring and analyzing the proteome. Its Nautilus Platform provides an end-to-end solution that includes instruments, consumables, and software analysis for proteomics workflows.

Valuation — source: SEC EDGAR (first-party)
Price$2.26
Market Cap$348.20M
P/E Ratio-5.0
Price / Book2.01
DCF Value (model)$-6.89
DCF Upside vs Price-404.9%
Profitability & Growth — source: SEC EDGAR
Return on Equity-39.5%
Current Ratio11.85
Valuation vs Sector & Industry
Stock P/E-5.0
Sector P/E (Technology)32.6
Industry P/E (Measuring & Control Equipment)60.1
vs Sector-115.2%
vs Industry-108.3%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holdera16z Capital Management, L.L.C. ($68.50M)
Institutional Holders Tracked10
Company
SectorTechnology
IndustryMeasuring & Control Equipment
CEOSujal Patel
Employees134
CountryUS
IPO Date2020-08-07

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Profound Medical Corp. (PROF)
  • KORU Medical Systems, Inc. (KRMD)
  • SANUWAVE Health, Inc. (SNWV)
  • Geospace Technologies Corporation (GEOS)
  • Orchestra BioMed Holdings, Inc. (OBIO)
  • Quantum-Si incorporated (QSI)
  • Sanara MedTech Inc. (SMTI)
  • Stereotaxis, Inc. (STXS)
NAUT earnings history · NAUT institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.